Seelos therapeutics announces 1-for-16 reverse stock split

New york, sept. 25, 2024 /prnewswire/ -- seelos therapeutics, inc. (nasdaq:  seel ) ("seelos" or the "company"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that its board of directors approved a 1-for-16 reverse stock split of its outstanding shares of common stock, to be effective as of 12:01 a.m.
SEEL Ratings Summary
SEEL Quant Ranking